Do you feel the ACR RA guidelines are sufficient? #RheumJC to explore this issue in Thursday's Twitter chat.
Secukinumab will be the focus of the next Rheumatology Journal Club (#RheumJC) Twitter chat at 4 p.m. and 10 p.m. EST on May 5.
A study in Rheumatology shows that joint damage in rheumatoid arthritis is down by about 50 percent in 25 years, which aligns with what physicians are seeing in practice - including a reduction in joint replacement surgery referrals.
Biologic drugs are incredibly versatile. Made by living cells and typically a protein, a single biologic can work in many different ways on a wide variety of diseases.
Belimumab has been a ground-breaking therapy for patients with systemic lupus erythematosus. In this op-ed, Paul Sufka, M.D., reviews recent studies on belimumab which could lead to new uses.
In this op-ed, specialty medicine experts address the value of biosimilars in specialty care. Value, they write, is a "three-legged stool supported by efficacy, toxicity and cost."
There must be uninterrupted supply of approved biosimilars and safety should be an utmost concern on all levels, CreakyJoints says.
"I remain cautiously optimistic that competition will improve patient access, as I support formal postmarketing surveillance in the form of registries as I welcome CT-P13."
Tools measuring a patient’s self-reported fatigue, sleep disturbance or depression aren’t usually tracked in the doctor’s office.
Physician describes his account of PQRS and Meaningful Use, which he says is unethical.